Pharma & Healthcare
Global Anti-VEGF Intravitreal Drugs Market Research Report 2026
- Mar 17, 26
- ID: 741377
- Pages: 117
- Figures: 113
- Views: 2
This report delivers a comprehensive overview of the global Anti-VEGF Intravitreal Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-VEGF Intravitreal Drugs. The Anti-VEGF Intravitreal Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Anti-VEGF Intravitreal Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Anti-VEGF Intravitreal Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Novartis
Biogen
Coherus BioSciences
Regeneron Pharmaceuticals
Samsung Bioepis
Biocon Biologics
Qilu Pharma
Chengdu Kanghong Pharmaceutical
Segment by Type
Ranibizumab
Aflibercept
Conbercept
Brolucizumab
Faricimab
Other
by Application
Age-related Macular Degeneration
Diabetic Macular Edema
Retinal Vein Occlusion
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Anti-VEGF Intravitreal Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Anti-VEGF Intravitreal Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Anti-VEGF Intravitreal Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Anti-VEGF Intravitreal Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Novartis
Biogen
Coherus BioSciences
Regeneron Pharmaceuticals
Samsung Bioepis
Biocon Biologics
Qilu Pharma
Chengdu Kanghong Pharmaceutical
Segment by Type
Ranibizumab
Aflibercept
Conbercept
Brolucizumab
Faricimab
Other
by Application
Age-related Macular Degeneration
Diabetic Macular Edema
Retinal Vein Occlusion
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Anti-VEGF Intravitreal Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Anti-VEGF Intravitreal Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Anti-VEGF Intravitreal Drugs Market Overview
1.1 Product Definition
1.2 Anti-VEGF Intravitreal Drugs by Type
1.2.1 Global Anti-VEGF Intravitreal Drugs Market Value by Type: 2025 vs 2032
1.2.2 Ranibizumab
1.2.3 Aflibercept
1.2.4 Conbercept
1.2.5 Brolucizumab
1.2.6 Faricimab
1.2.7 Other
1.3 Anti-VEGF Intravitreal Drugs by Application
1.3.1 Global Anti-VEGF Intravitreal Drugs Market Value by Application: 2025 vs 2032
1.3.2 Age-related Macular Degeneration
1.3.3 Diabetic Macular Edema
1.3.4 Retinal Vein Occlusion
1.3.5 Other
1.4 Global Anti-VEGF Intravitreal Drugs Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Intravitreal Drugs Revenue 2021–2032
1.4.2 Global Anti-VEGF Intravitreal Drugs Sales 2021–2032
1.4.3 Global Anti-VEGF Intravitreal Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Anti-VEGF Intravitreal Drugs Market Competition by Manufacturers
2.1 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Anti-VEGF Intravitreal Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Anti-VEGF Intravitreal Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Date of Entry into the Industry
2.8 Global Anti-VEGF Intravitreal Drugs Market Competitive Situation and Trends
2.8.1 Global Anti-VEGF Intravitreal Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Anti-VEGF Intravitreal Drugs Players Market Share by Revenue
2.8.3 Global Anti-VEGF Intravitreal Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Anti-VEGF Intravitreal Drugs Market Scenario by Region
3.1 Global Anti-VEGF Intravitreal Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2021–2032
3.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2021–2026
3.2.2 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2027–2032
3.3 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2021–2032
3.3.1 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2021–2026
3.3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2027–2032
3.4 North America Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Anti-VEGF Intravitreal Drugs Sales by Country (2021–2032)
3.4.3 North America Anti-VEGF Intravitreal Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Anti-VEGF Intravitreal Drugs Sales by Country (2021–2032)
3.5.3 Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGF Intravitreal Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Anti-VEGF Intravitreal Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Anti-VEGF Intravitreal Drugs Sales by Country (2021–2032)
3.7.3 Latin America Anti-VEGF Intravitreal Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021–2032)
4.1.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021–2026)
4.1.2 Global Anti-VEGF Intravitreal Drugs Sales by Type (2027–2032)
4.1.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021–2032)
4.2 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021–2032)
4.2.1 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021–2026)
4.2.2 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2027–2032)
4.2.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Anti-VEGF Intravitreal Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021–2032)
5.1.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021–2026)
5.1.2 Global Anti-VEGF Intravitreal Drugs Sales by Application (2027–2032)
5.1.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021–2032)
5.2 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021–2032)
5.2.1 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021–2026)
5.2.2 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2027–2032)
5.2.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Anti-VEGF Intravitreal Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Anti-VEGF Intravitreal Drugs Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Novartis Anti-VEGF Intravitreal Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Biogen
6.3.1 Biogen Company Information
6.3.2 Biogen Description and Business Overview
6.3.3 Biogen Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Biogen Anti-VEGF Intravitreal Drugs Product Portfolio
6.3.5 Biogen Recent Developments/Updates
6.4 Coherus BioSciences
6.4.1 Coherus BioSciences Company Information
6.4.2 Coherus BioSciences Description and Business Overview
6.4.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolio
6.4.5 Coherus BioSciences Recent Developments/Updates
6.5 Regeneron Pharmaceuticals
6.5.1 Regeneron Pharmaceuticals Company Information
6.5.2 Regeneron Pharmaceuticals Description and Business Overview
6.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolio
6.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.6 Samsung Bioepis
6.6.1 Samsung Bioepis Company Information
6.6.2 Samsung Bioepis Description and Business Overview
6.6.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolio
6.6.5 Samsung Bioepis Recent Developments/Updates
6.7 Biocon Biologics
6.7.1 Biocon Biologics Company Information
6.7.2 Biocon Biologics Description and Business Overview
6.7.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolio
6.7.5 Biocon Biologics Recent Developments/Updates
6.8 Qilu Pharma
6.8.1 Qilu Pharma Company Information
6.8.2 Qilu Pharma Description and Business Overview
6.8.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolio
6.8.5 Qilu Pharma Recent Developments/Updates
6.9 Chengdu Kanghong Pharmaceutical
6.9.1 Chengdu Kanghong Pharmaceutical Company Information
6.9.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.9.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolio
6.9.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Intravitreal Drugs Industry Chain Analysis
7.2 Anti-VEGF Intravitreal Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Intravitreal Drugs Production Mode & Process Analysis
7.4 Anti-VEGF Intravitreal Drugs Sales and Marketing
7.4.1 Anti-VEGF Intravitreal Drugs Sales Channels
7.4.2 Anti-VEGF Intravitreal Drugs Distributors
7.5 Anti-VEGF Intravitreal Drugs Customer Analysis
8 Anti-VEGF Intravitreal Drugs Market Dynamics
8.1 Anti-VEGF Intravitreal Drugs Industry Trends
8.2 Anti-VEGF Intravitreal Drugs Market Drivers
8.3 Anti-VEGF Intravitreal Drugs Market Challenges
8.4 Anti-VEGF Intravitreal Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Anti-VEGF Intravitreal Drugs by Type
1.2.1 Global Anti-VEGF Intravitreal Drugs Market Value by Type: 2025 vs 2032
1.2.2 Ranibizumab
1.2.3 Aflibercept
1.2.4 Conbercept
1.2.5 Brolucizumab
1.2.6 Faricimab
1.2.7 Other
1.3 Anti-VEGF Intravitreal Drugs by Application
1.3.1 Global Anti-VEGF Intravitreal Drugs Market Value by Application: 2025 vs 2032
1.3.2 Age-related Macular Degeneration
1.3.3 Diabetic Macular Edema
1.3.4 Retinal Vein Occlusion
1.3.5 Other
1.4 Global Anti-VEGF Intravitreal Drugs Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Intravitreal Drugs Revenue 2021–2032
1.4.2 Global Anti-VEGF Intravitreal Drugs Sales 2021–2032
1.4.3 Global Anti-VEGF Intravitreal Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Anti-VEGF Intravitreal Drugs Market Competition by Manufacturers
2.1 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Anti-VEGF Intravitreal Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Anti-VEGF Intravitreal Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Date of Entry into the Industry
2.8 Global Anti-VEGF Intravitreal Drugs Market Competitive Situation and Trends
2.8.1 Global Anti-VEGF Intravitreal Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Anti-VEGF Intravitreal Drugs Players Market Share by Revenue
2.8.3 Global Anti-VEGF Intravitreal Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Anti-VEGF Intravitreal Drugs Market Scenario by Region
3.1 Global Anti-VEGF Intravitreal Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2021–2032
3.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2021–2026
3.2.2 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2027–2032
3.3 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2021–2032
3.3.1 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2021–2026
3.3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2027–2032
3.4 North America Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Anti-VEGF Intravitreal Drugs Sales by Country (2021–2032)
3.4.3 North America Anti-VEGF Intravitreal Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Anti-VEGF Intravitreal Drugs Sales by Country (2021–2032)
3.5.3 Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGF Intravitreal Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Anti-VEGF Intravitreal Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Anti-VEGF Intravitreal Drugs Sales by Country (2021–2032)
3.7.3 Latin America Anti-VEGF Intravitreal Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021–2032)
4.1.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021–2026)
4.1.2 Global Anti-VEGF Intravitreal Drugs Sales by Type (2027–2032)
4.1.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021–2032)
4.2 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021–2032)
4.2.1 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021–2026)
4.2.2 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2027–2032)
4.2.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Anti-VEGF Intravitreal Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021–2032)
5.1.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021–2026)
5.1.2 Global Anti-VEGF Intravitreal Drugs Sales by Application (2027–2032)
5.1.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021–2032)
5.2 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021–2032)
5.2.1 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021–2026)
5.2.2 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2027–2032)
5.2.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Anti-VEGF Intravitreal Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Anti-VEGF Intravitreal Drugs Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Novartis Anti-VEGF Intravitreal Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Biogen
6.3.1 Biogen Company Information
6.3.2 Biogen Description and Business Overview
6.3.3 Biogen Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Biogen Anti-VEGF Intravitreal Drugs Product Portfolio
6.3.5 Biogen Recent Developments/Updates
6.4 Coherus BioSciences
6.4.1 Coherus BioSciences Company Information
6.4.2 Coherus BioSciences Description and Business Overview
6.4.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolio
6.4.5 Coherus BioSciences Recent Developments/Updates
6.5 Regeneron Pharmaceuticals
6.5.1 Regeneron Pharmaceuticals Company Information
6.5.2 Regeneron Pharmaceuticals Description and Business Overview
6.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolio
6.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.6 Samsung Bioepis
6.6.1 Samsung Bioepis Company Information
6.6.2 Samsung Bioepis Description and Business Overview
6.6.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolio
6.6.5 Samsung Bioepis Recent Developments/Updates
6.7 Biocon Biologics
6.7.1 Biocon Biologics Company Information
6.7.2 Biocon Biologics Description and Business Overview
6.7.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolio
6.7.5 Biocon Biologics Recent Developments/Updates
6.8 Qilu Pharma
6.8.1 Qilu Pharma Company Information
6.8.2 Qilu Pharma Description and Business Overview
6.8.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolio
6.8.5 Qilu Pharma Recent Developments/Updates
6.9 Chengdu Kanghong Pharmaceutical
6.9.1 Chengdu Kanghong Pharmaceutical Company Information
6.9.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.9.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolio
6.9.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Intravitreal Drugs Industry Chain Analysis
7.2 Anti-VEGF Intravitreal Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Intravitreal Drugs Production Mode & Process Analysis
7.4 Anti-VEGF Intravitreal Drugs Sales and Marketing
7.4.1 Anti-VEGF Intravitreal Drugs Sales Channels
7.4.2 Anti-VEGF Intravitreal Drugs Distributors
7.5 Anti-VEGF Intravitreal Drugs Customer Analysis
8 Anti-VEGF Intravitreal Drugs Market Dynamics
8.1 Anti-VEGF Intravitreal Drugs Industry Trends
8.2 Anti-VEGF Intravitreal Drugs Market Drivers
8.3 Anti-VEGF Intravitreal Drugs Market Challenges
8.4 Anti-VEGF Intravitreal Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Anti-VEGF Intravitreal Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Anti-VEGF Intravitreal Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Anti-VEGF Intravitreal Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Anti-VEGF Intravitreal Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Anti-VEGF Intravitreal Drugs Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Anti-VEGF Intravitreal Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGF Intravitreal Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Anti-VEGF Intravitreal Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Intravitreal Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Anti-VEGF Intravitreal Drugs Sales by Region (K Dose), 2021–2026
Table 18. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Anti-VEGF Intravitreal Drugs Sales by Region (K Dose), 2027–2032
Table 20. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Anti-VEGF Intravitreal Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Anti-VEGF Intravitreal Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Anti-VEGF Intravitreal Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2021–2026
Table 27. North America Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2027–2032
Table 28. North America Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Anti-VEGF Intravitreal Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2021–2026
Table 32. Europe Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2027–2032
Table 33. Europe Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Anti-VEGF Intravitreal Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2021–2026
Table 42. Latin America Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2027–2032
Table 43. Latin America Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Type (2021–2026)
Table 51. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Type (2027–2032)
Table 52. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Type (2021–2026)
Table 59. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Type (2027–2032)
Table 60. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Application (2021–2026)
Table 61. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Application (2027–2032)
Table 62. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Application (2021–2026)
Table 69. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Roche Anti-VEGF Intravitreal Drugs Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Novartis Anti-VEGF Intravitreal Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. Biogen Company Information
Table 81. Biogen Description and Business Overview
Table 82. Biogen Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. Biogen Anti-VEGF Intravitreal Drugs Product
Table 84. Biogen Recent Developments/Updates
Table 85. Coherus BioSciences Company Information
Table 86. Coherus BioSciences Description and Business Overview
Table 87. Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Coherus BioSciences Anti-VEGF Intravitreal Drugs Product
Table 89. Coherus BioSciences Recent Developments/Updates
Table 90. Regeneron Pharmaceuticals Company Information
Table 91. Regeneron Pharmaceuticals Description and Business Overview
Table 92. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product
Table 94. Regeneron Pharmaceuticals Recent Developments/Updates
Table 95. Samsung Bioepis Company Information
Table 96. Samsung Bioepis Description and Business Overview
Table 97. Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Samsung Bioepis Anti-VEGF Intravitreal Drugs Product
Table 99. Samsung Bioepis Recent Developments/Updates
Table 100. Biocon Biologics Company Information
Table 101. Biocon Biologics Description and Business Overview
Table 102. Biocon Biologics Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Biocon Biologics Anti-VEGF Intravitreal Drugs Product
Table 104. Biocon Biologics Recent Developments/Updates
Table 105. Qilu Pharma Company Information
Table 106. Qilu Pharma Description and Business Overview
Table 107. Qilu Pharma Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Qilu Pharma Anti-VEGF Intravitreal Drugs Product
Table 109. Qilu Pharma Recent Developments/Updates
Table 110. Chengdu Kanghong Pharmaceutical Company Information
Table 111. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 112. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 113. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product
Table 114. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Anti-VEGF Intravitreal Drugs Distributors List
Table 118. Anti-VEGF Intravitreal Drugs Customers List
Table 119. Anti-VEGF Intravitreal Drugs Market Trends
Table 120. Anti-VEGF Intravitreal Drugs Market Drivers
Table 121. Anti-VEGF Intravitreal Drugs Market Challenges
Table 122. Anti-VEGF Intravitreal Drugs Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Product Picture of Anti-VEGF Intravitreal Drugs
Figure 2. Global Anti-VEGF Intravitreal Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Anti-VEGF Intravitreal Drugs Market Share by Type: 2025 & 2032
Figure 4. Ranibizumab Product Picture
Figure 5. Aflibercept Product Picture
Figure 6. Conbercept Product Picture
Figure 7. Brolucizumab Product Picture
Figure 8. Faricimab Product Picture
Figure 9. Other Product Picture
Figure 10. Global Anti-VEGF Intravitreal Drugs Market Value by Application (US$ Million), 2021–2032
Figure 11. Global Anti-VEGF Intravitreal Drugs Market Share by Application: 2025 & 2032
Figure 12. Age-related Macular Degeneration
Figure 13. Diabetic Macular Edema
Figure 14. Retinal Vein Occlusion
Figure 15. Other
Figure 16. Global Anti-VEGF Intravitreal Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Anti-VEGF Intravitreal Drugs Market Size (US$ Million), 2021–2032
Figure 18. Global Anti-VEGF Intravitreal Drugs Sales (K Dose), 2021–2032
Figure 19. Global Anti-VEGF Intravitreal Drugs Average Price (US$/Dose), 2021–2032
Figure 20. Anti-VEGF Intravitreal Drugs Report Years Considered
Figure 21. Anti-VEGF Intravitreal Drugs Sales Share by Manufacturers in 2025
Figure 22. Global Anti-VEGF Intravitreal Drugs Revenue Share by Manufacturers in 2025
Figure 23. Top 5 and Top 10 Global Anti-VEGF Intravitreal Drugs Players: Market Share by Revenue in Anti-VEGF Intravitreal Drugs in 2025
Figure 24. Anti-VEGF Intravitreal Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 25. Global Anti-VEGF Intravitreal Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 26. North America Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021–2032)
Figure 27. North America Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2021–2032)
Figure 28. United States Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Canada Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Europe Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021–2032)
Figure 31. Europe Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2021–2032)
Figure 32. Germany Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. France Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. U.K. Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Italy Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Russia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Asia Pacific Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2021–2032)
Figure 38. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2021–2032)
Figure 39. China Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Japan Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. South Korea Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. India Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Australia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. China Taiwan Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Southeast Asia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Latin America Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021–2032)
Figure 47. Latin America Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2021–2032)
Figure 48. Mexico Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Brazil Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Argentina Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Colombia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Middle East and Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021–2032)
Figure 53. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2021–2032)
Figure 54. Turkey Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Saudi Arabia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. UAE Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Global Sales Market Share of Anti-VEGF Intravitreal Drugs by Type (2021–2032)
Figure 58. Global Revenue Market Share of Anti-VEGF Intravitreal Drugs by Type (2021–2032)
Figure 59. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Type (2021–2032)
Figure 60. Global Sales Market Share of Anti-VEGF Intravitreal Drugs by Application (2021–2032)
Figure 61. Global Revenue Market Share of Anti-VEGF Intravitreal Drugs by Application (2021–2032)
Figure 62. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Application (2021–2032)
Figure 63. Anti-VEGF Intravitreal Drugs Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Anti-VEGF Intravitreal Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Anti-VEGF Intravitreal Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Anti-VEGF Intravitreal Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Anti-VEGF Intravitreal Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Anti-VEGF Intravitreal Drugs Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Anti-VEGF Intravitreal Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Anti-VEGF Intravitreal Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGF Intravitreal Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Anti-VEGF Intravitreal Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Intravitreal Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Anti-VEGF Intravitreal Drugs Sales by Region (K Dose), 2021–2026
Table 18. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Anti-VEGF Intravitreal Drugs Sales by Region (K Dose), 2027–2032
Table 20. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Anti-VEGF Intravitreal Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Anti-VEGF Intravitreal Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Anti-VEGF Intravitreal Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2021–2026
Table 27. North America Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2027–2032
Table 28. North America Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Anti-VEGF Intravitreal Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2021–2026
Table 32. Europe Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2027–2032
Table 33. Europe Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Anti-VEGF Intravitreal Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2021–2026
Table 42. Latin America Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2027–2032
Table 43. Latin America Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Type (2021–2026)
Table 51. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Type (2027–2032)
Table 52. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Type (2021–2026)
Table 59. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Type (2027–2032)
Table 60. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Application (2021–2026)
Table 61. Global Anti-VEGF Intravitreal Drugs Sales (K Dose) by Application (2027–2032)
Table 62. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Application (2021–2026)
Table 69. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Roche Anti-VEGF Intravitreal Drugs Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Novartis Anti-VEGF Intravitreal Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. Biogen Company Information
Table 81. Biogen Description and Business Overview
Table 82. Biogen Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. Biogen Anti-VEGF Intravitreal Drugs Product
Table 84. Biogen Recent Developments/Updates
Table 85. Coherus BioSciences Company Information
Table 86. Coherus BioSciences Description and Business Overview
Table 87. Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Coherus BioSciences Anti-VEGF Intravitreal Drugs Product
Table 89. Coherus BioSciences Recent Developments/Updates
Table 90. Regeneron Pharmaceuticals Company Information
Table 91. Regeneron Pharmaceuticals Description and Business Overview
Table 92. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product
Table 94. Regeneron Pharmaceuticals Recent Developments/Updates
Table 95. Samsung Bioepis Company Information
Table 96. Samsung Bioepis Description and Business Overview
Table 97. Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Samsung Bioepis Anti-VEGF Intravitreal Drugs Product
Table 99. Samsung Bioepis Recent Developments/Updates
Table 100. Biocon Biologics Company Information
Table 101. Biocon Biologics Description and Business Overview
Table 102. Biocon Biologics Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Biocon Biologics Anti-VEGF Intravitreal Drugs Product
Table 104. Biocon Biologics Recent Developments/Updates
Table 105. Qilu Pharma Company Information
Table 106. Qilu Pharma Description and Business Overview
Table 107. Qilu Pharma Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Qilu Pharma Anti-VEGF Intravitreal Drugs Product
Table 109. Qilu Pharma Recent Developments/Updates
Table 110. Chengdu Kanghong Pharmaceutical Company Information
Table 111. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 112. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 113. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product
Table 114. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Anti-VEGF Intravitreal Drugs Distributors List
Table 118. Anti-VEGF Intravitreal Drugs Customers List
Table 119. Anti-VEGF Intravitreal Drugs Market Trends
Table 120. Anti-VEGF Intravitreal Drugs Market Drivers
Table 121. Anti-VEGF Intravitreal Drugs Market Challenges
Table 122. Anti-VEGF Intravitreal Drugs Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Product Picture of Anti-VEGF Intravitreal Drugs
Figure 2. Global Anti-VEGF Intravitreal Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Anti-VEGF Intravitreal Drugs Market Share by Type: 2025 & 2032
Figure 4. Ranibizumab Product Picture
Figure 5. Aflibercept Product Picture
Figure 6. Conbercept Product Picture
Figure 7. Brolucizumab Product Picture
Figure 8. Faricimab Product Picture
Figure 9. Other Product Picture
Figure 10. Global Anti-VEGF Intravitreal Drugs Market Value by Application (US$ Million), 2021–2032
Figure 11. Global Anti-VEGF Intravitreal Drugs Market Share by Application: 2025 & 2032
Figure 12. Age-related Macular Degeneration
Figure 13. Diabetic Macular Edema
Figure 14. Retinal Vein Occlusion
Figure 15. Other
Figure 16. Global Anti-VEGF Intravitreal Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Anti-VEGF Intravitreal Drugs Market Size (US$ Million), 2021–2032
Figure 18. Global Anti-VEGF Intravitreal Drugs Sales (K Dose), 2021–2032
Figure 19. Global Anti-VEGF Intravitreal Drugs Average Price (US$/Dose), 2021–2032
Figure 20. Anti-VEGF Intravitreal Drugs Report Years Considered
Figure 21. Anti-VEGF Intravitreal Drugs Sales Share by Manufacturers in 2025
Figure 22. Global Anti-VEGF Intravitreal Drugs Revenue Share by Manufacturers in 2025
Figure 23. Top 5 and Top 10 Global Anti-VEGF Intravitreal Drugs Players: Market Share by Revenue in Anti-VEGF Intravitreal Drugs in 2025
Figure 24. Anti-VEGF Intravitreal Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 25. Global Anti-VEGF Intravitreal Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 26. North America Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021–2032)
Figure 27. North America Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2021–2032)
Figure 28. United States Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Canada Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Europe Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021–2032)
Figure 31. Europe Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2021–2032)
Figure 32. Germany Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. France Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. U.K. Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Italy Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Russia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Asia Pacific Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2021–2032)
Figure 38. Asia Pacific Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2021–2032)
Figure 39. China Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Japan Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. South Korea Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. India Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Australia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. China Taiwan Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Southeast Asia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Latin America Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021–2032)
Figure 47. Latin America Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2021–2032)
Figure 48. Mexico Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Brazil Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Argentina Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Colombia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Middle East and Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2021–2032)
Figure 53. Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2021–2032)
Figure 54. Turkey Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Saudi Arabia Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. UAE Anti-VEGF Intravitreal Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Global Sales Market Share of Anti-VEGF Intravitreal Drugs by Type (2021–2032)
Figure 58. Global Revenue Market Share of Anti-VEGF Intravitreal Drugs by Type (2021–2032)
Figure 59. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Type (2021–2032)
Figure 60. Global Sales Market Share of Anti-VEGF Intravitreal Drugs by Application (2021–2032)
Figure 61. Global Revenue Market Share of Anti-VEGF Intravitreal Drugs by Application (2021–2032)
Figure 62. Global Anti-VEGF Intravitreal Drugs Price (US$/Dose) by Application (2021–2032)
Figure 63. Anti-VEGF Intravitreal Drugs Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232